Lupin receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets

Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, to market a generic equivalent of Juluca® Tablets, 50 mg/25 mg of ViiV Healthcare Company.

Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca®) had estimated annual sales of USD 666 million in the U.S. (IQVIA MAT September 2022).

Shares of Lupin Limited was last trading in BSE at Rs. 755.60 as compared to the previous close of Rs. 754.95. The total number of shares traded during the day was 19197 in over 1541 trades.

The stock hit an intraday high of Rs. 758.85 and intraday low of 747.15. The net turnover during the day was Rs. 14480350.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 TentativeApproval USFDA ANDA Dolutegravir Rilpivirine Tablets